The role of carbonic anhydrase in de novo lipid synthesis was examined by measuring [1-14C]acetate incorporation into total lipids, fatty acids and non-saponifiable lipids in freshly isolated rat hepatocytes. Two carbonic anhydrase inhibitors, trifluoromethylsulphonamide (TFMS) and ethoxozolamide (ETZ) decreased incorporation of 14C into total lipids. Both fatty acid and non-saponifiable lipid components of the total lipid were inhibited to approximately the same extent by 100 ,M TFMS (29 + 0.3 % and 35 + 0.3 % of control respectively in replicate studies). However, neither drug significantly affected ATP concentrations or the transport activity of Na+/K+-ATPase, two measures of cell viability. To establish the site of this inhibition, water-soluble 14C-labelled metabolites from perchloric acid extracts of the radiolabelled cells were separated by ion-exchange chromatography. TFMS inhibited 14C incorporation into citrate, malate, a-oxoglutarate and fumarate, but had no effect on
INTRODUCTION
Hepatocytes contain a relatively high specific activity of carbonic anhydrase due mainly to the presence of a mitochondrial matrix isoenzyme (CA V, [1] [2] [3] [4] [5] [6] [7] [8] ) and two cytosolic forms (CA II and CA III, [3, [9] [10] [11] ). Metabolic roles for the hepatic isoenzymes have been investigated, particularly with regard to their possible involvement in pathways that utilize bicarbonate. Carbonic anhydrase catalyses the following readily reversible reaction: H20 + CO2-HC03 +H+ The interconversion of CO2 and HCO3-is important because CO bond angles change considerably when CO2 is converted into HCO3-(for review see ref. [12] ). Therefore, in metabolic reactions or transport processes that require bicarbonate, CO2 is a poor substitute and vice versa [13] . Unlike many enzymically catalysed reactions, this reaction proceeds to a significant extent in the absence of enzyme. Drugs that completely inhibit carbonic anhydrase activity therefore only partially inhibit the rate of the reaction. As a result carbonic anhydrase inhibitors only partially inhibit reactions or transport processes that consume CO2, HCO3-or H+.
Sulphonamide carbonic anhydrase inhibitors (SCAIs) have been reported to inhibit de novo fatty acid synthesis in hepatocytes [14] and human adipose tissue [15] . In 1984, Herbert and Coulson [14] hypothesized that this inhibition might represent an interaction between acetyl-CoA carboxylase, a bicarbonate-requiring enzyme, and the cytosolic carbonic anhydrases. This idea stemmed from the inhibition in vitro of acetyl-CoA carboxylase incorporation of 14C into acetoacetate. Since ATP citrate-lyase, the cytosolic enzyme that catalyses the conversion of citrate into acetyl-CoA, catalyses an early rate-limiting step in fatty acid synthesis, levels of cytosolic citrate may be rate controlling for de novo fatty acid and sterol synthesis. Indeed citrate concentrations were significantly reduced to 37 + 6 % of control in hepatocytes incubated with 100 #M TFMS for 30 min. TFMS also inhibited the incorporation of 14C from [1-14C] by SCAIs reported earlier by Cao and Rous [16] and interactions that were being reported between carbonic anhydrase V and two other carboxylases. For instance, SCAIs had been observed to inhibit urea synthesis [2] [3] [4] [17] [18] [19] and gluconeogenesis from pyruvate, but not glutamine [3, 4, 12, [19] [20] [21] . There was good evidence that the effects of SCAIs on urea synthesis and gluconeogenesis were at the level of carbonic anhydrase V, which in turn was thought to provide additional bicarbonate for carbamoylphosphate synthetase and pyruvate carboxylase, enzymes involved in these respective processes [2] [3] [4] 12, [17] [18] [19] [20] [21] .
In this report, we have examined the mechanism underlying the inhibition of fatty acid synthesis by SCAIs in freshly isolated rat hepatocytes. In agreement with Herbert and Coulson [14] , who were studying reptiles, we report that SCAIs inhibit de novo lipid synthesis in rat hepatocytes. However, they also inhibited de novo synthesis of non-saponifiable lipids, which does not require acetyl-CoA carboxylase, but does share other earlier metabolic steps with de novo fatty acid synthesis. To determine whether or not an earlier step in the pathway might be blocked by SCAIs, the metabolic fate of [1-_4C] [23] . Briefly, water (0.8 ml) was added to each ice-cold cell pellet (approx. 0.2 ml) followed by 3.8 ml of chloroform/methanol (1:2, v/v). The pellets were vortexed and shaken for several hours. After centrifugation, the supernatant was removed and the pellet was re-extracted with chloroform/methanol/0.2 M HCI (1:2:0.8, v/v). The supernatants were pooled, combined with 2.5 ml of chloroform and 2.5 ml of water and centrifuged to form two phases. The aqueous layer was discarded. The organic phase was extracted with another 5 ml of water which was also discarded after centrifugation. An aliquot of this organic phase was measured by liquid-scintillation counting to determine the incorporation of 14C into total lipid.
To measure the incorporation of 14C into fatty acids and nonsaponifiable lipids a fraction of the organic phase was evaporated to approx. 0.1 ml under vacuum in a Jouan RC 10.10 centrifuge. To saponify the evaporated samples, 2.5 ml of ethanol and 0.1 ml of 33 % KOH was added. The capped samples were heated overnight at 75 'C. After the tubes had cooled to room temperature, the contents were combined with 1 drop of phenolphthalein indicator solution, 2.5 ml of water and 5 ml of ether. After vortexing and centrifugation, the organic phase was removed and the aqueous phase was re-extracted with ether. To determine the incorporation of 14C into non-saponifiable lipids, radioactivity content of these ether extracts was quantified by liquid-scintillation counting. The aqueous phase was acidified with 0.3 ml of 6 M HC1, and fatty acids were extracted with ether as above. To determine the incorporation of 14C into fatty acids, radioactivity in these ether extracts was also quantified.
Determination of [ATP] and [citrate]
Cell suspensions were incubated for 45 min with 100 nM insulin and TFMS or drug vehicle (DMSO). Aliquots of the cells (1 ml) were centrifuged through 10 ml of ice-cold 10 % sucrose. The pellets were resuspended in ice-cold 2 % perchloric acid using a sonicator. The perchloric acid (2 %) extracts were then neutralized with a solution containing 3 M KOH, 0.5 M Mops buffer and 0.1 M EDTA. After centrifugation to remove the potassium perchlorate, dilutions of the supernatants were analysed for ATP using a commercially available bioluminescence method (Boehringer-Mannheim). The light signal was measured in an EG&G Berthold AutoLumat LB953 luminometer. Citrate was determined spectrophotometrically using the method described by Williamson and Corkey [24] , which couples citrate lyase and malate dehydrogenase.
Na+/K+-ATPase-medlated transport
Ouabain-sensitive 86Rb+ uptake was measured as an index of Na+/K+-ATPase-mediated transport activity as described by Lynch et al. [22, 25] . Briefly, cell suspensions (5 ml per 25 ml flask) were incubated for 30 min in the presence or absence of 2 mM ouabain and/or SCAIs at 37°C in a shaking water bath under an atmosphere of 95 % 02/5 % CO2. Uptake measurements were initiated by adding 86RbCl (final concentration 1.08 x 106-1.15 x 106 d.p.m./ml cell suspension). Uptake was stopped after 5 min by centrifuging cells through 10 To identify the peaks, the elution pattern was compared with that ofstandard compounds run in parallel. Most ofthe standards were radiolabelled and quantified by liquid-scintillation counting. The only exception was acetoacetate which was determined using a commercially available kit (Miles Laboratories). The column was regenerated with 25 ml of0.1 M HCI followed by water until the pH of the eluate was 4.0. l l l very potent SCAIs [29] . It differs from classic sulphonamides, such as ETZ, in that it contains an aliphatic rather than a heterocyclic residue on the sulphonamide. As a result of their structural differences, it is unlikely that both heterocyclic and aliphatic sulphonamides would have the same non-specific effects. Incubation of the cells with 100 ,uM TFMS resulted in a 60-70 % decrease in de novo lipid synthesis ( Figure 1 and Table 1 (Figure 3 ).
RESULTS

DISCUSSION
The purpose of this paper was to learn whether or not carbonic anhydrase activity is an important factor in de novo lipid synthesis. The results showed that inhibition of carbonic anhydrase inhibits lipid synthesis ( Figure 1 and Table 1 ) apparently because carbonic anhydrase activity is required for optimal activity of pyruvate carboxylase rather than because it may be necessary for acetyl-CoA carboxylase activity. We considered the possibility that these effects might have reflected a cytotoxic or non-specific action of SCAIs. Until recently only heterocyclic SCAIs were available, so it was difficult to discount the possibility that effects observed with these drugs were not due to non-specific interactions of the heterocyclic residue. This is an important consideration as Beynen and Geelen [30] have reported that a number of cytotoxic cyclic compounds can inhibit lipogenesis. To address this problem, we have used TFMS, a member of a new class of aliphatic carbonic anhydrase inhibitors [29] , in addition to the heterocyclic inhibitor, ETZ. Both compounds inhibited de novo lipogenesis (Table 1) , but neither lowered ATP concentrations or the transport activity of the ATP-requiring enzyme, Na+/K+-ATPase (Table 2) . Thus it seems unlikely that their effects on de novo lipogenesis represented cytotoxicity. In fact, the observation that two structurally different SCAIs have the same effect supports the conclusion that their actions are secondary to carbonic anhydrase inhibition. TFMS and ETZ inhibited the de novo synthesis of both fatty acids and non-saponifiable lipids by approx. 60-70 % ( [14, 20] performed studies in vivo on reptiles with heterocycic SCAIs . They also observed inhibition of de novo fatty acid synthesis by SCAIs. By this time, however, several groups had reported an interaction between the mitochondrial carbonic anhydrase (isoenzyme V) and both pyruvate carboxylase and carbamoyl phosphate synthetase [2] [3] [4] 12, [17] [18] [19] [20] [21] . Herbert and Coulson [14, 20] [34] ). However, 13C-NMR studies show that even in the fed state (i.e. where lipogenesis is favoured) the ratio of flux through hepatic pyruvate carboxylase and pyruvate dehydrogenase is still about 1.2:1, i.e. favouring pyruvate carboxylase [35] . Our studies indicate that radiolabel incorporated into citrate is significant. It is important to remember that the carbons that are removed from the citric acid cycle via citrate for lipid synthesis are only partially returned and that demands for citric acid cycle intermediates by other metabolic processes (e.g. gluconeogenesis, ureagenesis, amino acid synthesis) may occur simultaneously, even when lipogenesis is favoured. That is where the anaplerotic activity of pyruvate carboxylase, and the mitochondrial carbonic anhydrase which assists it, becomes important. If during lipogenesis, the ratio of flux through hepatic pyruvate carboxylase and pyruvate dehydrogenase fell below 1:1 (i.e. favouring pyruvate dehydrogenase as is often depicted), we would predict that the levels of citric acid cycle intermediates would soon decline to levels sufficient for ATP production, but insufficient to maintain maximal rates of lipid synthesis, as indicated by our
